Coherus Oncology (CHRS) investor relations material

Strategic transformation and financial highlights

• Transitioned to a focused oncology company after acquiring Surface Oncology in 2023 and divesting biosimilar assets, paying down $480 million in debt and adding $250 million to the balance sheet.

• Secured $483 million upfront and $75 million in follow-on payments from the UDENYCA divestiture, with high confidence in receiving the latter by end of 2024 and early 2027.

• Raised $50 million recently, investing $10–$15 million to expand the commercial team and infrastructure to accelerate market penetration.

Product pipeline and clinical development

• LOQTORZI, a next-generation PD-1 inhibitor, is positioned as both a revenue generator and multiplier, with expanded indications expected to drive substantial sales growth.

• Tagmokitug (CCR8 Treg depleter) and casdozokitug (anti-IL-27) are advancing in multiple cancer indications, with promising early efficacy and durability data.

• Collaboration with J&J for tagmokitug in prostate cancer marks the first CCR8/T cell engager combination in this indication.

Commercial performance and projections

• LOQTORZI sales more than doubled from $19.1 million in 2024 to $40.8 million in 2025, with a target of 10–15% quarterly growth.

• Projected to reach 70% market share and $175 million annualized sales by 2028, covering all commercial costs by 2027.

• Investments in data acquisition and sales force expansion aim to accelerate maximal market penetration.